Laurus Labs LAURUSLABS
API maker (ARVs, oncology, CVS) turning into a CDMO (Laurus Synthesis) with formulations and Laurus Bio
Mapped in 1 theme: Pharmaceuticals.
Where Laurus Labs sits in the supply chain
Laurus Labs appears in 2 supply-chain layers in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 5,041 | 5,554 | 6,813 |
| Net profit | 162 | 358 | 890 |
Latest-year revenue ₹6,813 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- CDMO-led recovery: FY26 profit ₹890 Cr vs ₹162 Cr in FY24
- Large chemistry capacity in Visakhapatnam; stock more than doubled in the year to Oct 2026
Risks
- ARV API pricing depends on global tenders
- Very rich valuation leaves no margin for CDMO delays
- Customer concentration in large CDMO contracts
Common questions
What does Laurus Labs do?
API maker (ARVs, oncology, CVS) turning into a CDMO (Laurus Synthesis) with formulations and Laurus Bio.
Where does Laurus Labs sit in the supply chain?
Laurus Labs (NSE: LAURUSLABS) is mapped in 2 supply-chain layers: APIs (active ingredients) (Pharmaceuticals) and CDMO & contract research (Pharmaceuticals).
Who are Laurus Labs' peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Divi's Laboratories, Aarti Drugs, Solara Active Pharma Sciences, Concord Biotech, Granules India, Neuland Laboratories and 2 more.
What is Laurus Labs' market cap and valuation?
As of 30 Oct 2026: market cap ₹1.30L Cr, P/E 97.0x, ROCE 17.8%, ROE 18.3%, dividend yield 0.08%.